A synthetic peptide analog of alpha-MSH used to treat hypoactive sexual desire disorder by activating melanocortin receptors to enhance sexual arousal.
This review explains how the brain’s melanocortin receptors (especially MC3R and MC4R) control hunger, weight and energy use, and lists the drugs that can activate them, including the peptide bremelanotide (pt‑141). It shows that bremelanotide is already approved for low sexual desire and hints it might affect metabolism, but it doesn’t give new dosing rules or direct protocols for biohackers.
Scientists mapped the exact shape of the MC4R protein when it’s hooked up to its natural hormone and to drugs like bremelanotide (pt‑141). This shows how these molecules stick to the receptor and turn it on, giving clues for making better weight‑loss or performance‑boosting compounds.
Cipriani. Sarah S; Alfaroli. Chiara C; Maseroli. Elisa E; Vignozzi. Linda L
Bremelanotide (pt‑141) is a peptide that can boost sexual desire by activating brain pathways linked to the melanocortin system. In trials with pre‑menopausal women who have low sexual desire, it showed a modest improvement on questionnaires but caused nausea in about 40% of users. The overall benefit is limited and the studies are hard to interpret because of strong placebo effects and subjective outcome measures.
This paper explains that women can suffer from a lack of sexual desire called HSDD, which can be distressing and is linked to many factors. It highlights simple screening tools doctors can use and notes that two drugs are FDA‑approved: flibanserin and the peptide bremelanotide (pt‑141). The authors urge more research and awareness so patients get proper treatment.
Koochaki. Patricia P; Revicki. Dennis D; Wilson. Hilary H; Pokrzywinski. Robin R; Jordan. Robert R;...
A study of up to 242 pre‑menopausal women showed that the peptide bremelanotide (also called PT‑141) noticeably boosted sexual desire, physical arousal, and overall sexual satisfaction compared with a placebo, and participants reported better communication with partners. The findings are based on patient‑filled exit surveys and interviews after a double‑blind trial.
Clayton. Anita H AH; Kingsberg. Sheryl A SA; Portman. David D; Sadiq. Amama A; Krop. Julie J; Jordan...
Bremelanotide (pt‑141) is safe enough for short‑term use but causes nausea, flushing, headache and occasional skin darkening, especially if taken every day. It can raise blood pressure a bit and may lower levels of indomethacin and naltrexone, so watch your heart health and avoid daily dosing unless you’re okay with skin changes.
Women with high blood pressure often have more sexual problems. Some blood pressure medicines like beta‑blockers can worsen them, while ARBs may improve sexual function. For pre‑menopausal women, the peptide bremelanotide (pt‑141) and flibanserin are options; for post‑menopausal women, hormone‑based drugs are preferred.
This study shows that the peptide bremelanotide (pt‑141), which activates melanocortin receptors, can cause erections and boost sexual activity in animal tests by acting on the brain and possibly the genitals.
Cocchetti. Carlotta C; Ristori. Jiska J; Mazzoli. Francesca F; Vignozzi. Linda L; Maggi. Mario M; Fi...
This review says that low sexual desire is common in transgender women and suggests looking at biological, mental, and social factors before treating. It lists possible help like sex‑therapy, certain brain‑acting drugs (flibanserin, bremelanotide/pt‑141, bupropion, buspirone) and skin patches of testosterone, but warns testosterone might cause unwanted male traits and notes there isn’t solid data on how well these work specifically for trans women.
Revicki. Dennis A DA; Althof. Stanley E SE; Derogatis. Leonard R LR; Kingsberg. Sheryl A SA; Wilson....
A new questionnaire (EDQ) reliably measures sexual desire in women, and in two big studies the peptide drug bremelanotide (PT‑141) showed a clear boost in desire compared to placebo over six months.
The paper reviews drugs that can help with sexual problems in people assigned female at birth, especially after menopause or with low sexual desire. It notes that bremelanotide (also called PT‑141) is a safe, centrally‑acting option that can boost desire and satisfaction, alongside other hormones like estrogen, testosterone, and flibanserin.
The paper reviews brain‑acting drugs like nasal bremelanotide (pt‑141) that might help men who can’t use Viagra or similar pills, but the data are still limited and they aren’t approved yet.
Pfaus. James G JG; Sadiq. Amama A; Spana. Carl C; Clayton. Anita H AH
Bremelanotide (pt‑141) is a drug that activates certain brain receptors (MC4R) linked to sexual desire, boosting dopamine release in a key hypothalamic area, which may help women with low sexual desire, but the paper only explains how it works, not how to use it.
da Silva Lara. Lucia A LA; Rufino. Andrea C AC; Oliveira. Flávia F FF; Rossato. Serena S; Borge...
This review looks at many ways to treat low sexual desire and other problems in women. Hormone therapy, testosterone, and a drug called flibanserin help menopausal and pre‑menopausal women feel more desire. The peptide bremelanotide (also called PT‑141) was shown to boost desire, arousal, and orgasm, while talk‑based therapies like CBT and mindfulness also work. No single treatment is considered the best yet.
Simon. James A JA; Kingsberg. Sheryl A SA; Portman. David D; Williams. Laura A LA; Krop. Julie J; Jo...
A big study looked at the drug bremelanotide (also called pt‑141) taken by pre‑menopausal women who have low sexual desire. Over a year of open‑label use, the drug kept improving desire scores and was generally safe, with the most common side effects being nausea, flushing and headache. No new safety problems showed up, but many participants stopped early, so the long‑term data are from a smaller group.
White. William B WB; Myers. Martin G MG; Jordan. Robert R; Lucas. Johna J
Bremelanotide (pt‑141) can cause a tiny, short‑lived rise in blood pressure—about 2‑3 mmHg—right after you inject it, and the higher dose also drops your heart rate a few beats per minute. The spike usually lasts less than 15 minutes and isn’t dangerous for most healthy people, but it’s worth watching if you have any blood‑pressure issues.
A recent review says drugs that act on the brain, like the peptide PT‑141 (bremelanotide), can improve female sexual problems and might work best when combined with other treatments such as hormones or counseling.
King. Stephen H SH; Mayorov. Alexander V AV; Balse-Srinivasan. Preeti P; Hruby. Victor J VJ; Vandera...
PT-141 (bremelanotide) is a peptide that works in the brain, not the blood vessels, to trigger erections by activating melanocortin receptors, especially MC4R. It’s already in Phase II human trials and may also boost sexual desire, offering a different approach from typical ED drugs.
New brain‑acting drugs, especially bremelanotide (also called PT‑141), are being studied for helping both men and women with sexual problems. They work by influencing brain areas and chemicals that control desire and performance, and could be used alongside or instead of typical pills like Viagra. The research is still early, so there’s no clear dosing guide yet, but the idea is that targeting the central nervous system might improve sexual health.
Pfaus. James J; Giuliano. François F; Gelez. Hélène H
In rats, the peptide bremelanotide (pt‑141) boosts the female’s urge to mate—shown by more solicitation moves—when given under the skin or directly into a brain area called the medial preoptic area. It doesn’t change other sexual actions, and it seems to work by turning on dopamine signals in that brain region. While this points to a possible way to treat low sexual desire, the data are only from animal studies, so real‑world use in people is still uncertain.